Affinity Asset Advisors, LLC Annovis Bio, Inc. Transaction History
Affinity Asset Advisors, LLC
- $596 Million
- Q2 2025
A detailed history of Affinity Asset Advisors, LLC transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 72,900 shares of ANVS stock, worth $164,753. This represents 0.13% of its overall portfolio holdings.
Number of Shares
72,900Holding current value
$164,753% of portfolio
0.13%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding ANVS
# of Institutions
50Shares Held
1.82MCall Options Held
102KPut Options Held
98.3K-
Vanguard Group Inc Valley Forge, PA697KShares$1.57 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA183KShares$414,2280.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA165KShares$371,9010.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$227,6020.0% of portfolio
-
Merit Financial Group, LLC91.3KShares$206,3740.0% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $18.5M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...